SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:227cb10b-6946-49d6-a2ea-e888171771b4"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:227cb10b-6946-49d6-a2ea-e888171771b4" > Efficacy of human l...

  • Weiland, OKarolinska Institutet (författare)

Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection

  • Artikel/kapitelEngelska1995

Förlag, utgivningsår, omfång ...

  • Informa UK Limited,1995

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:227cb10b-6946-49d6-a2ea-e888171771b4
  • https://lup.lub.lu.se/record/1108828URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:28588128URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:28658063URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:1945911URI
  • https://doi.org/10.3109/00365549509032724DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • A total of 42 Swedish patients with biopsy-proven chronic hepatitis C virus (HCV) infection were treated with a natural human leucocyte alpha-interferon (HuIFN-alpha-Le), Alfanative (BioNative AB, Umeå, Sweden) in an open uncontrolled study. Two patients were withdrawn from treatment within 2 weeks due to non-compliance and were omitted from further analysis, and 40 patients (17 females), mean age 39 years (range 24-71) completed the study. All patients were HCV RNA-positive in serum prior to treatment, with raised alanine aminotransferase (ALT) levels > 1.5 times the upper normal limit known for more than 6 months. Interferon was given at a dose of 3 MU t.i.w. for an intended 24 weeks and follow-up was a further 24 weeks after treatment. Biochemical non-responders were withdrawn from treatment within 12-16 weeks but continued follow-up. Overall 21/40 (52.5%) patients had a complete biochemical response with normal ALT levels at the end of treatment. Sustained response during follow-up was seen in 8 (20%) whereas 13 (32.5%) had a non-sustained response. At the end of treatment 23 (58%) patients had undetectable serum HCV RNA and 9 (23%) at follow-up. Patients with sustained, non-sustained and non-response had a mean pretreatment HCV RNA level of 3.2 x 10(5), 2.5 x 10(6) and 3.2 x 10(6) genomes/ml, respectively, differences that did not reach statistical significance. Of the patients 3, 9, 10 and 14 had genotype 1b, 3a, 1a, and 2b, respectively, and 4 had mixed genotypes. Of the 23 patients with genotype 2b or 3a, 7 had a sustained response vs. none of the 13 patients with genotype 1a or 1b (p = 0.03). No patients with cirrhosis had a sustained response whereas 4/18 with chronic persistent and 4/18 with chronic active hepatitis had such a response. It is concluded that some 50% of patients treated with HuIFN-alpha-Le responded with normalisation of ALT levels but that only 20% had a durable response 24 weeks post-treatment, and that patients with genotypes 3a or 2b seem to respond better than patients with other genotypes.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Chen, MKarolinska Institutet (författare)
  • Lindh, GKarolinska Institutet (författare)
  • Mattsson, L (författare)
  • Schvarcz, RKarolinska Institutet (författare)
  • Sonnerborg, AKarolinska Institutet (författare)
  • Wahl, M (författare)
  • Wejstal, R (författare)
  • Widell, AndersLund University,Lunds universitet,Klinisk mikrobiologi, Malmö,Forskargrupper vid Lunds universitet,Clinical Microbiology, Malmö,Lund University Research Groups(Swepub:lu)mikr-awi (författare)
  • Norkrans, G (författare)
  • Karolinska InstitutetKlinisk mikrobiologi, Malmö (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Scandinavian Journal of Infectious Diseases: Informa UK Limited27:5, s. 319-3241651-19800036-5548

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy